Alan Sabirsh

AstraZeneca (Sweden)

Papers

1

Total Citations

54

H-Index

1

About

Alan Sabirsh is a leading researcher in the field of nanomedicine and drug delivery, with a particular focus on the design and optimization of dendrimer-based systems for nucleic acid therapeutics. His most cited work, a 2023 study on precise end group chemistry modifications of PAMAM and poly(L-lysine) dendrimers, has garnered 54 citations and represents a major contribution to overcoming the critical barrier of cytosolic mRNA delivery. By systematically engineering the surface chemistry of these polymers, Sabirsh demonstrated how subtle structural changes can dramatically enhance endosomal escape and transfection efficiency, providing a rational design framework for next-generation gene therapies. This work has significant implications for the development of mRNA vaccines and treatments for genetic disorders. Sabirsh’s research is distinguished by its rigorous, systematic approach to polymer chemistry, bridging fundamental materials science with translational biomedical applications. His findings are widely cited by groups working on non-viral vectors, highlighting his impact on the field.

Research Focus

Key Achievements

1
H-Index
1
Papers
54
Total Citations
54
Avg Citations/Paper
🏆 Most Cited Paper
Precise and systematic end group chemistry modifications on PAMAM and poly(l-lysine) dendrimers to improve cytosolic delivery of mRNA
54 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: AstraZeneca (Sweden)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago